Rani Therapeutics (RANI) Competitors $0.71 -0.04 (-5.46%) Closing price 04:00 PM EasternExtended Trading$0.71 +0.00 (+0.25%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RANI vs. NLTX, EPRX, ACRS, ADCT, LRMR, EDIT, GLSI, TARA, SCPH, and LYELShould you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Aclaris Therapeutics (ACRS), ADC Therapeutics (ADCT), Larimar Therapeutics (LRMR), Editas Medicine (EDIT), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), scPharmaceuticals (SCPH), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Rani Therapeutics vs. Neoleukin Therapeutics Eupraxia Pharmaceuticals Aclaris Therapeutics ADC Therapeutics Larimar Therapeutics Editas Medicine Greenwich LifeSciences Protara Therapeutics scPharmaceuticals Lyell Immunopharma Neoleukin Therapeutics (NASDAQ:NLTX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Do insiders and institutionals have more ownership in NLTX or RANI? 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 53.3% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, NLTX or RANI? Rani Therapeutics has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-6.28Rani Therapeutics$1.20M35.88-$33.97M-$0.99-0.76 Is NLTX or RANI more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Rani Therapeutics N/A -219.64%-56.71% Which has more volatility & risk, NLTX or RANI? Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Does the MarketBeat Community believe in NLTX or RANI? Neoleukin Therapeutics received 15 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Rani Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Rani TherapeuticsOutperform Votes3583.33% Underperform Votes716.67% Does the media favor NLTX or RANI? In the previous week, Rani Therapeutics had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 2 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.37 beat Rani Therapeutics' score of -0.11 indicating that Neoleukin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neoleukin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate NLTX or RANI? Rani Therapeutics has a consensus price target of $9.40, indicating a potential upside of 1,154.84%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryRani Therapeutics beats Neoleukin Therapeutics on 11 of the 17 factors compared between the two stocks. Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RANI vs. The Competition Export to ExcelMetricRani TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.24M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.719.1426.7920.05Price / Sales35.88255.59394.72116.44Price / CashN/A65.8538.2534.62Price / Book1.476.546.864.61Net Income-$33.97M$143.51M$3.22B$248.19M7 Day Performance34.54%5.60%6.83%2.97%1 Month Performance-31.28%10.06%13.73%16.58%1 Year Performance-85.43%-0.86%18.22%8.16% Rani Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RANIRani Therapeutics2.0823 of 5 stars$0.71-5.5%$9.40+1,227.3%-85.7%$40.71M$1.20M-0.67110Analyst RevisionGap DownNLTXNeoleukin TherapeuticsN/A$14.73-1.8%N/A-42.6%$138.43MN/A-4.7490Gap UpHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.2192 of 5 stars$3.86+1.4%$10.50+172.4%+32.2%$138.20MN/A-5.3529Gap UpACRSAclaris Therapeutics2.8957 of 5 stars$1.25-0.8%$10.67+753.3%+13.4%$135.35M$18.72M-2.40100Gap UpADCTADC Therapeutics2.6933 of 5 stars$1.35+5.9%$7.75+476.2%-47.8%$133.39M$70.84M-0.56310News CoverageEarnings ReportAnalyst RevisionLRMRLarimar Therapeutics2.0657 of 5 stars$2.08-1.9%$19.63+843.5%-71.7%$133.18MN/A-1.8130Positive NewsEDITEditas Medicine4.3025 of 5 stars$1.54+6.2%$5.73+271.9%-70.3%$128.91M$32.31M-0.60230Gap DownGLSIGreenwich LifeSciences1.337 of 5 stars$9.58+1.6%$39.00+307.1%-21.3%$127.17MN/A-11.973Earnings ReportTARAProtara Therapeutics2.1845 of 5 stars$3.27+0.9%$20.40+523.9%+16.4%$126.15MN/A-1.1630Positive NewsGap UpSCPHscPharmaceuticals4.1728 of 5 stars$2.48+1.6%$14.00+464.5%-18.6%$124.70M$36.33M-1.3130Earnings ReportAnalyst RevisionLYELLyell Immunopharma2.9755 of 5 stars$0.42+5.4%$1.00+137.2%-84.2%$124.52M$61,000.00-0.53270Positive NewsGap Down Related Companies and Tools Related Companies NLTX Alternatives EPRX Alternatives ACRS Alternatives ADCT Alternatives LRMR Alternatives EDIT Alternatives GLSI Alternatives TARA Alternatives SCPH Alternatives LYEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RANI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
